Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108, a Novel Potent Tropomyosin Receptor Kinase Inhibitor

ABSTRACT Tropomyosin receptor kinase (Trk) inhibitors are an essential class of anticancer drugs treating NTRK gene fusions‐positive cancer. However, the potential for the emergence of on‐target resistance suggests newer Trk inhibitors with low drug resistance risk are needed. LPM4870108 is a novel...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaochen Zhang, Baiyang Yuan, Chunmei Li, Hongbo Wang, Shujuan Wei, Jingwei Tian, Sijin Duan
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Pharmacology Research & Perspectives
Subjects:
Online Access:https://doi.org/10.1002/prp2.70153
Tags: Add Tag
No Tags, Be the first to tag this record!